Hinge Health (NYSE:HNGE) Stock Price Target Raised at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised Hinge Health’s price target to $135 from $130 while maintaining a “buy” rating, implying 17.27% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with an average target of $111.60.
• Hinge Health reported strong quarterly results, including $234.97 million in revenue, 52.4% year-over-year growth, and $0.71 in EPS versus the $0.27 consensus estimate.
• Shares opened at $115.11, near their 52-week high of $118.87, while valuation remains elevated at roughly 89 times earnings. Insiders sold more than 1 million shares worth approximately $95.6 million over the past quarter, adding a potential risk for investors.

Hinge Health (NYSE:HNGE - Get Free Report) had its target price lifted by stock analysts at Stifel Nicolaus from $130.00 to $135.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. Stifel Nicolaus's target price points to a potential upside of 17.27% from the stock's previous close.

A number of other analysts have also recently weighed in on HNGE. Citizens Jmp boosted their target price on shares of Hinge Health from $96.00 to $107.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 5th. Robert W. Baird raised their target price on Hinge Health from $85.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 22nd. Morgan Stanley raised their target price on Hinge Health from $72.00 to $108.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Barclays lifted their target price on Hinge Health from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, October 12th. Finally, Weiss Ratings lowered Hinge Health from a "hold (c)" rating to a "hold (c-)" rating in a research report on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $111.60.

Hinge Health Stock Performance

Shares of HNGE opened at $115.11 on Tuesday. Hinge Health has a 52-week low of $30.08 and a 52-week high of $118.87. The firm has a market cap of $9.29 billion, a price-to-earnings ratio of 89.36 and a beta of 1.37. The business's fifty day moving average is $98.66 and its 200-day moving average is $67.35.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.44. The business had revenue of $234.97 million during the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. Hinge Health's quarterly revenue was up 52.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.02) earnings per share. As a group, research analysts forecast that Hinge Health will post 1.25 EPS for the current fiscal year.

Insider Activity

In other news, Chairman Gabriel Mecklenburg sold 250,000 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $88.97, for a total transaction of $22,242,500.00. Following the completion of the sale, the chairman directly owned 250,000 shares in the company, valued at $22,242,500. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of Hinge Health stock in a transaction on Friday, August 21st. The stock was sold at an average price of $88.05, for a total transaction of $2,905,650.00. Following the transaction, the president directly owned 706,235 shares of the company's stock, valued at $62,183,991.75. This represents a 4.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,024,581 shares of company stock worth $95,632,761 over the last quarter. Company insiders own 18.92% of the company's stock.

Institutional Trading of Hinge Health

Institutional investors have recently bought and sold shares of the company. Argent Capital Management LLC bought a new stake in Hinge Health during the 3rd quarter valued at $3,376,000. Assenagon Asset Management S.A. raised its holdings in Hinge Health by 2,141.9% during the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company's stock worth $180,373,000 after buying an additional 1,772,182 shares during the last quarter. Vista Investment Partners LLC bought a new position in shares of Hinge Health in the second quarter valued at $3,468,000. 11.2 Capital Management LLC bought a new position in shares of Hinge Health in the second quarter valued at $204,566,531. Finally, Tidal Investments LLC acquired a new position in shares of Hinge Health during the second quarter valued at about $925,000.

Hinge Health News Summary

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Quarterly results exceeded consensus. Hinge Health generated approximately $235.0 million in revenue, up 52.4% year over year, and reported $0.71 in earnings per share versus estimates ranging from $0.27 to $0.63. The company also posted a 15.15% net margin, reinforcing the improving profitability story. Hinge Health reports record third quarter 2026 financial results
• Positive Sentiment: Management provided a constructive growth outlook. Hinge Health outlined 2026 revenue of $879 million to $881 million, representing another upward outlook adjustment according to coverage of the earnings call. The company also is targeting an integrated gastrointestinal care program for summer 2027, creating a potential new expansion opportunity beyond its core musculoskeletal business. Hinge Health outlines revenue outlook and GI program
• Neutral Sentiment: The earnings reaction was relatively limited. Although Hinge Health cleared published estimates and highlighted record results, reports characterized the stock’s response as muted. With a market capitalization near $9.3 billion, a price-to-earnings ratio around 89, and shares close to their one-year high, much of the strong execution may already be reflected in the valuation. Hinge Health third-quarter results beat forecasts
• Negative Sentiment: Expectations remain a key risk. Some coverage indicated that results missed the higher “whisper” forecast despite beating official consensus estimates. That gap, combined with the stock’s sharp appreciation above its 50-day and 200-day moving averages, could limit further gains unless Hinge Health continues delivering sizable revenue growth and upward guidance revisions. Hinge Health clears consensus but misses the whisper

About Hinge Health

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.